Cipla's sorafenib priced at one-tenth of Nexavar in India
This article was originally published in Scrip
Cipla has firmed up launch plans for its generic version of Bayer's anticancer, Nexavar (sorafenib tosylate), in India.
You may also be interested in...
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.